Menu
Back to User profile » Dr Shahid Siddiqui
Papers published by Dr Shahid Siddiqui:
Dupilumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma Irrespective of Baseline Asthma Characteristics
Busse WW, Pavord ID, Siddiqui S, Khan AH, Praestgaard A, Nash S, Jacob-Nara JA, Rowe PJ, Deniz Y
Journal of Asthma and Allergy 2023, 16:411-419
Published Date: 18 April 2023
Clinical Efficacy among Patients with Chronic Rhinosinusitis with Nasal Polyps and Clinical Features of Obstructive Lung Disease: Post Hoc Analysis of the Phase III SINUS-24 and SINUS-52 Studies
Maspero JF, Bachert C, Martinez FJ, Hanania NA, Ortiz B, Patel N, Mannent LP, Praestgaard A, Pandit-Abid N, Siddiqui S, Hardin M
Journal of Asthma and Allergy 2023, 16:333-342
Published Date: 31 March 2023
Real-World Cost of Nasal Polyps Surgery and Risk of Major Complications in the United States: A Descriptive Retrospective Database Analysis [Corrigendum]
Ge W, Wang D, Chuang CC, Li Y, Rout R, Siddiqui S, Kamat S
ClinicoEconomics and Outcomes Research 2023, 15:209-211
Published Date: 29 March 2023
Health-Related Quality of Life Impairment Among Patients with Severe Chronic Rhinosinusitis with Nasal Polyps in the SINUS-24 Trial
Maspero JF, Khan AH, Philpott C, Hellings PW, Hopkins C, Wagenmann M, Siddiqui S, Msihid J, Nash S, Chuang CC, Kamat S, Rowe PJ, Deniz Y, Jacob-Nara JA
Journal of Asthma and Allergy 2023, 16:323-332
Published Date: 29 March 2023
Real-World Cost of Nasal Polyps Surgery and Risk of Major Complications in the United States: A Descriptive Retrospective Database Analysis
Ge W, Wang D, Chuang CC, Li Y, Rout R, Siddiqui S, Kamat S
ClinicoEconomics and Outcomes Research 2022, 14:691-697
Published Date: 7 November 2022
Improvement in Health-Related Quality of Life with Dupilumab in Patients with Moderate-to-Severe Asthma with Comorbid Chronic Rhinosinusitis with/without Nasal Polyps: An Analysis of the QUEST Study
Hopkins C, Buchheit KM, Heffler E, Cohen NA, Olze H, Khan AH, Msihid J, Siddiqui S, Nash S, Jacob-Nara JA, Rowe PJ, Deniz Y
Journal of Asthma and Allergy 2022, 15:767-773
Published Date: 7 June 2022
Rapid and Continuing Improvements in Nasal Symptoms with Dupilumab in Patients with Severe CRSwNP
Bachert C, Khan AH, Hopkins C, Blaiss MS, Soler ZM, Nash S, Siddiqui S, Praestgaard A, Deniz Y, Rowe PJ, Jacob-Nara JA
Journal of Asthma and Allergy 2022, 15:557-563
Published Date: 4 May 2022
Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD
Chen R, Zhong N, Wang HY, Zhao L, Mei X, Qin Z, Huang J, Assam PN, Maes A, Siddiqui S, Martin UJ, Reisner C
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:43-56
Published Date: 8 January 2020
Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA
Lipworth BJ, Collier DJ, Gon Y, Zhong NS, Nishi K, Chen R, Arora S, Maes A, Siddiqui S, Reisner C, Martin UJ
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:2969-2984
Published Date: 26 September 2018
Functional performance in patients with COPD: association with treatment regimen, GOLD group, lung function, and symptom burden in a cross-sectional study
Ding B, Judge D, Small M, Bent-Ennakhil N, Siddiqui S
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:2785-2796
Published Date: 7 September 2018
A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD
De Backer W, De Backer J, Vos W, Verlinden I, Van Holsbeke C, Clukers J, Hajian B, Siddiqui S, Jenkins M, Reisner C, Martin UJ
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:2673-2684
Published Date: 30 August 2018
Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD
Fukushima Y, Nakatani Y, Ide Y, Sekino H, St Rose E, Siddiqui S, Maes A, Reisner C
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:1187-1194
Published Date: 13 April 2018
Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD
Ferguson GT, Rodriguez-Roisin R, Reisner C, Maes A, Siddiqui S, Martin UJ
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:945-953
Published Date: 21 March 2018
Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE2SPOND rationale and study design
Rennard SI, Martinez FJ, Rabe KF, Sethi S, Pizzichini E, McIvor A, Siddiqui S, Anzueto A, Zhu H
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:1921-1928
Published Date: 17 August 2016